secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001641172-25-001987
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2 for neuropathic pain
--------------------------------------------------------------------------------

- Phase 1 trial of oral ketamine analog Ketamir-2 for neuropathic pain; 56 healthy volunteers in SAD/MAD cohorts.
- Preclinical data showed superior efficacy vs. pregabalin and gabapentin in validated neuropathic pain models.
- Study completion expected Q4 2025; Phase 2a in diabetic neuropathic pain to start by year-end 2025.
- First human efficacy data anticipated in first half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225001987/0001641172-25-001987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225001987/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer